Zydus Lifesciences has made a significant breakthrough in the fight against typhoid fever. The company's Typhoid Vi conjugate vaccine, ZyVac TCV, has received prequalification from the World Health Organization (WHO), making it eligible for purchase by United Nations (UN) agencies. This is a major milestone, as the vaccine will now be distributed globally, particularly in regions with high typhoid prevalence, such as India, Africa, and Southeast Asia.
ZyVac TCV is an indigenously developed and manufactured vaccine, produced at the Zydus Biotech Park in Ahmedabad. It's designed to provide active immunization against Salmonella typhi infections in individuals.
The vaccine's prequalification opens doors for Zydus to participate in UN agencies' procurement programs, which acquire approximately 150 million doses of typhoid conjugate vaccines annually.
Key Highlights:
ZyVac TCV Prequalification: WHO prequalifies Zydus' Typhoid Vi conjugate vaccine for UN procurement.
Vaccine Availability: Eligible for purchase by UN agencies and distribution in high-risk regions.
Age Group: Suitable for individuals aged 6 months to 65 years.
Global Impact: Expected to combat typhoid fever in regions with high prevalence.
Typhoid fever is a serious concern, especially in South Asia, where India alone accounts for 75% of incidence and mortality.
The WHO's Strategic Advisory Group of Experts on Immunization (SAGE) highlights that 27% of severe typhoid cases occur in children under five years old.
The prequalification of ZyVac TCV is expected to make a substantial impact in combating typhoid fever, particularly in high-risk areas. Indian multinational pharmaceutical company Zydus Lifesciences' shares have already seen a positive response, trading at ₹1,006.70, up by ₹18.50 or 1.87% on the NSE.
(Input From Various Sources)
(Rehash/Neha Kamble/MSM)